Clinical Trial Update: Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on epicardial delivery of hiPSC-derived cardiomyocytes for severe chronic ischemic heart failure. The trial is Phase 1/2 and currently not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Ischemic Heart Disease

Drugs mentioned

• hiPSC-derived cardiomyocytes (epicardial delivery) (human induced pluripotent stem cell-derived cardiomyocytes)

Snippet

Sponsor: HELP Therapeutics Co., Ltd. | Conditions: Heart Failure | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING